Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760018 | 0.88 | HDAC1 (0.43) | HDAC1PTPN1HDAC3NCOR2CYP17A1 | |
| SCHEMBL1705492 | 0.83 | HDAC1 (0.51) | HDAC1PTPN1HDAC3NCOR2CYP17A1 | |
| SCHEMBL26170484 | 0.83 | CYP17A1 (0.48) | HDAC1PTPN1HDAC3CYP17A1KCNQ4 | |
| SCHEMBL3760016 | 0.81 | HDAC2 (0.63) | HDAC1PTPN1HDAC3NCOR2HDAC2 | |
| SCHEMBL1706877 | 0.80 | HDAC1 (0.46) | HDAC1HDAC3NCOR2KCNQ4KCNQ5 | |
| SCHEMBL14057611 | 0.79 | F10 (0.45) | HDAC1PTPN1HDAC3NCOR2CYP17A1 | |
| SCHEMBL25221573 | 0.79 | RORC (0.41) | HDAC1PTPN1HDAC3CYP17A1KCNQ4 | |
| SCHEMBL3771529 | 0.79 | WDR5 (0.42) | HDAC1PTPN1HDAC3NCOR2CYP17A1 | |
| SCHEMBL3766485 | 0.79 | HDAC2 (0.51) | HDAC1HDAC3NCOR2CYP17A1KCNQ4 | |
| SCHEMBL26170486 | 0.78 | CYP17A1 (0.42) | HDAC1HDAC3CYP17A1KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885PTPN1 4306/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.